MAGEA3 and non-small cell lung carcinoma: The most frequently associated CTAs to NSCLC were utilized with the objective of designing a multi-epitope vaccine that can potentially induce immune responses against NSCLC expressing MAGEA3, MAGEA4, NY-ESO-1, and KK-LC1.